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Platelets participate centrally in atherothrombosis, resulting in ves-
sel occlusion and ischaemia. Consequently, optimisation of an-
tiplatelet regimens has the potential to further reduce the residual
burden of morbidity and mortality associated with atherosclerosis.
Ticagrelor is a potent oral platelet P2Y12 receptor antagonist that (1)
inhibits a central amplification pathway of platelet activation directly
as well as via an active metabolite, (2) has a rapid onset and offset
of antiplatelet action that remains consistent in the circulation dur-
ing twice-daily administration and is amenable to reversal, (3) has
inverse agonist properties, and (4) demonstrates pleiotropic effects
that contribute to anti-thrombotic, anti-inflammatory and vasodila-
tory properties. These advantageous characteristics of ticagrelor
have translated to beneficial clinical outcomes in patients with acute
coronary syndromes or ischaemic stroke, during prolonged mainte-
nance therapy in specific high-risk populations, and following per-
cutaneous coronary intervention but not definitively following coro-
nary artery bypass graft surgery or in peripheral artery disease pa-
tients. Novel innovative strategies aim to reduce the risk of bleeding
during dual antiplatelet therapy via shortening the duration of treat-
ment and replacing the standard-of-care with ticagrelor monother-
apy. In cases where aspirin is an essential component in secondary
prevention, dose modification when combined with ticagrelor may
hypothetically provide desirable clinical outcomes following appro-
priate clinical assessment as predicted by pharmacological studies.
Overall, the future management of acute coronary syndromes could
potentially involve the dichotomisation of antithrombotic therapies,
whereby only those with high-risk of ischaemia, without a high-risk
of bleeding, receive ticagrelor plus very-low-dose aspirin, while tica-
grelor monotherapy is administered to the remaining majority.
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1. Introduction
The formation of atherosclerotic plaques increases the risk
of arterial thrombosis that can result in vascular occlusion
and subsequently ischaemia or infarction of the distal tissue.
The most devastating conditions that manifest clinically as a
result of this process include cardiovascular death, myocar-
dial infarction (MI) and stroke, otherwise collectively known
as major adverse cardiovascular events (MACE), markedly
contributing to the global burden of premature morbidity
and mortality [1]. In the coronary arteries, atherothrom-
bosis may present rapidly as an acute coronary syndrome
(ACS), which includes ST-elevation MI (STEMI) and non-
ST-elevation ACS (NSTE-ACS). Subclinical atherothrom-
bosis may also contribute to the progression of atheroscle-
rotic disease in patients with chronic coronary syndromes
(CCS), which includes so-called stable coronary artery dis-
ease (CAD) or an ACS event more than 1 year ago [2–6].
Platelets are central to this pathophysiological process and,
therefore, the development of antiplatelets aims to reduce the
risk of MACE by therapeutically antagonising various mech-
anisms involved in the activation and aggregation of platelets
[7]. The combined inhibition of thromboxane A2 (TXA2)
synthesis, a product of a chain of enzymes including platelet
cyclo-oxygenase (COX)-1, and platelet activation by adeno-
sine diphosphate (ADP) via the P2Y12 receptor in dual an-
tiplatelet therapy (DAPT) with aspirin and a platelet P2Y12
receptor antagonist (‘P2Y12 inhibitor’), respectively, forms
the cornerstone of management for ACS patients [2–6].
While contemporary advances have improved the con-
trol of modifiable risk factors, reduced complications associ-
ated with percutaneous coronary intervention (PCI) [8], and
reduced the risk of recurrent ischaemia post-ACS, there re-
mains a significant degree of residual risk in patients with
CAD. Ticagrelor provides several hypothetical and phar-
macological advantages over aspirin and other oral P2Y12
inhibitors that have the potential to optimise patient out-
comes in novel antiplatelet strategies by reducing the risk
of ischaemia in DAPT or reducing the risk of bleeding as a
monotherapy [9, 10]. In addition, these strategies may be ex-
tended to benefit patients with other atherosclerotic condi-
tions, such as ischaemic stroke and peripheral artery disease
(PAD). It has been almost a decade since our last review of the
clinical uses of ticagrelor [11], since when numerous large-
scale trials have been conducted (Table 1, Ref. [12–18], Table
2, Ref. [19–23] and Fig. 1). This review aims to summarise
pharmacological and clinical characteristics of ticagrelor and
highlight the latest guidelines, developments and future po-
tential in clinical practice.
Fig. 1. Visual abstract of randomised clinical trials and pre-specified sub-studies relevant to the clinical development of ticagrelor in
atherothrombotic disease, categorised by clinical disease and treatment strategy.
2. The role of the P2Y12 receptor in platelet
function
Platelets have a critical function within the vascular sys-
tem to regulate haemostasis. Injury to the vascular endothe-
lium exposes underlying extracellular matrix and prothrom-
botic factors, resulting in a cascade of events that stimu-
late platelet activation, a process involving structural shape
change, degranulation, and platelet aggregation. Degranula-
tion involves the release of pro-inflammatory and prothrom-
botic α-granules and dense granules, the latter containing a
high concentration of ADP. Aggregation involves activation
of the glycoprotein IIb/IIIa receptor, which allows adjacent
platelets to bind to each other via fibrinogen. Anumber of ag-
onists may initiate platelet activation including ADP, throm-
bin, TXA2, von Willebrand factor and collagen [24, 25].
Subsequently, the release of ADP from dense granules am-
plifies the platelet response regardless of the initial stimulus
and, therefore, ADP is considered a critical agonist involved
in platelet activation.
The nomenclature assigned to G-protein-coupled recep-
tors that are activated by nucleotides, such as ADP, is P2Y. To
date, eight of these purinergic receptors have been identified
[26], of which two are functionally present on the surface of
platelets: Gq-coupled P2Y1 and Gi-coupled P2Y12. Both are
required for ADP-induced platelet aggregation: P2Y1 activa-
tion initiates platelet activation and shape change, including
through mobilisation of intracellular calcium ions, whereas
P2Y12 activation amplifies this process [27, 28]. Inhibition
of either receptor is sufficient to inhibit ADP-induced platelet
aggregation [29].
The primary member of the Gi family that the P2Y12 re-
ceptor couples with is Gαi2 [25]. In response to ADP acti-
vation, the Gαi subunit inhibits adenylate cyclase which re-
sults in a reduction in cyclic adenosine monophosphate and
consequently reduces the phosphorylation of vasodilator-
stimulated phosphoprotein by protein kinase A. This sub-
sequently leads to glycoprotein IIb/IIIa activation, the final
mechanism involved in platelet aggregation [30–32]. Medi-
ated via Gi βγ subunits, P2Y12 activation also leads to acti-
vation of phosphoinositide 3-kinase (PI3K), Akt, Rap1b and
potassium channels, resulting in additional amplification of
platelet activation [25]. The importance of the PI3K pathway
in platelet activation and thrombosis has been emphasised in
PI3Kγ deficient mice that were protected from lethal ADP-
induced thromboembolism [33].
Antiplatelet drugs that targeted the P2Y12 receptor were
widely used before the receptor was cloned for the first time
in 2001 [25, 34]. Several ex-vivo studies have established the
P2Y12 receptor as a key component involved in the pro-
cess of haemostasis, particularly the potentiation of dense
granule secretion [35], glycoprotein IIb/IIIa activation [36–
38] and thrombosis [39, 40]. P2Y12 receptors contribute
to the generation of TXA2 under certain experimental con-
ditions [41] but this is of doubtful physiological relevance
[42]. Importantly, P2Y12 receptor activation also amplifies
the secretion of α-granules, upregulating pro-inflammatory
responses such as the expression of P-selectin on the platelet
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Fig. 2. Pharmacology of ticagrelor. Morphine slows gastric emptying and thereforemay delay the onset of action of ticagrelor, which is absorbed in the small
intestine. Once in the circulation, ticagrelor acts directly, as well as indirectly via ticagrelor active metabolite (TAM), as (1) a non-competitive antagonist and
inverse agonist of the P2Y12 platelet receptor; and (2) a weak antagonist of adenosine uptake via erythrocyte and platelet equilibrative nucleoside transporter-1
(ENT1). Platelet activation and subsequent degranulation leads to the release of ADP, which activates the P2Y12 receptor and initiates intracellular Gi-coupled
signalling pathways. Inhibition of adenylate cyclase (AC) reduces the cAMP/ PKA/PKG/VASP-P pathway by Giα, or activation of the PI3K/PKB/Akt/Rap1b
pathway by Giβγ, results in the activation of the glycoprotein (GP) IIb/IIIa integrin, leading to platelet aggregation and amplification of degranulation via an
‘outside-in’ signalling pathway. Alternatively, ENT1 antagonism has the potential to elevate extracellular adenosine that acts via at least three distinct pathways
that suppress the levels of VASP (A2A, IP and sGC activation) and therefore complement the effects of P2Y12 inhibition by ticagrelor.
surface and consequent platelet-leukocyte interactions [43,
44]. Therefore, it is evident that activation of the platelet
P2Y12 receptor plays a central role in the initiation and am-
plification of platelet activation and all the prothrombotic and
pro-inflammatory responses that accompany this (Fig. 2).
Considering that the P2Y12 receptor is constitutively ex-
pressed on platelets and a limited number of other cell types,
present in the central nervous system and on vascular smooth
muscle cells, this receptor represents a desirable target for an-
tiplatelet therapy [11].
3. Mechanism of action of ticagrelor
Ticagrelor, previously identified as AZD6140, belongs to
the cyclopentyl-triazolopyrimidine class of P2Y12 inhibitors
that possess structural similarities to the natural P2Y12 recep-
tor antagonist adenosine triphosphate (Fig. 3). In contrast to
other widely used oral P2Y12 inhibitors in the thienopyridine
subclass (clopidogrel and prasugrel), ticagrelor exerts its an-
tiplatelet activity by reversibly binding to the P2Y12 receptor
at a site that is distinct from the ADP binding site, resulting in
a non-competitive inhibition of the ADP-induced signalling
pathway [45]. This effect is also achieved by ticagrelor active
metabolite (TAM), which has similar potency [46]. Further-
more, ticagrelor demonstrates features of an inverse agonist,
whereby maintained treatment reduces the basal Gi-coupled
signalling in the absence of ADP stimulation [31, 47].
Interestingly, ticagrelor exerts a well-documented antag-
onistic effect on platelet and erythrocyte equilibrative nu-
cleoside transporter (ENT)1 (Fig. 2), potentially resulting in
an increase in extracellular adenosine by inhibiting cellular
adenosine uptake [10, 47–49]. Due to its low potency as
an ENT1 antagonist relative to its high potency as a P2Y12
inhibitor, the extent of this effect is marginal at therapeu-
tic concentrations of ticagrelor, as demonstrated by conflict-
ing results from different studies, with some studies [49–53]
but not others showing elevated plasma adenosine levels in
ticagrelor-treated patients [54]. Enhanced levels of extracel-
lular adenosine have the potential to contribute to the an-
tiplatelet response via the activation of Gs-coupled A2A re-
ceptors and resultant activation of adenylate cyclase [55]. Ef-
fects on adenosine metabolism have been purported to ex-
plain several advantageous pharmacological characteristics of
ticagrelor that are considered pleiotropic when compared to
thienopyridines, including: coronary vasodilation [56]; re-
duced myocardial infarct size secondary to the upregulation
and activation of cardio-protective COX-2 and endothelial
nitric oxide synthase [57]; and regulation of the innate im-
mune system [48].
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Fig. 3. Chemical structures of adenosine, adenosine triphosphate, AR-
C124910XX (ticagrelor active metabolite) and ticagrelor.
Considering that studies have shown ticagrelor to impact
coronary blood flow responses and severity of adenosine-
mediated side effects during adenosine infusions [56, 58], it
remains possible that ticagrelor affects adenosine concentra-
tions in localised tissues. Hypothetically there may be local
enhancement of adenosine concentration at the platelet cell
membrane, which may produce therapeutic effects that are
not reflected by measurements of systemic plasma adenosine
level [31]; however, this mechanism remains to be proven
and some preclinical studies have not confirmed a beneficial
adenosine-mediated effect of ticagrelor on infarct size [59].
The anti-inflammatory effects of ticagrelor may be an
important contributor to clinical outcomes. In an endo-
toxaemia model, there was evidence that ticagrelor exhib-
ited greater anti-inflammatory properties when compared to
clopidogrel. Both suppressed the release of tumour necro-
sis factor-α and interleukin (IL)-6, with greater effect of
ticagrelor treatment reflecting the higher associated level of
platelet P2Y12 inhibition [60]. Other studies have also iden-
tified anti-inflammatory effects of ticagrelor in mouse [61]
and human models [62]. The potential implications of this
is highlighted in studies that have, firstly, suggested that tica-
grelor inhibits thromboinflammatory processes and may im-
prove lung function in patients with pneumonia [63] and,
secondly, shown lower mortality as a result of pulmonary ad-
verse events and sepsis associated with ticagrelor compared
with clopidogrel treatment [64].
An in vitro study identified that ticagrelor, but not the
clopidogrel active metabolite, activates endothelial nitric ox-
ide synthase [65]. These effects were independent of P2Y12
or adenosine receptor mediation and therefore suggests that
alternative mechanisms are yet to be identified.
4. Pharmacokinetics of ticagrelor
Ticagrelor has a mean absolute oral bioavailability of 36%
[66]. The absorption of ticagrelor is rapid and reaches a max-
imum plasma concentration (tmax) within 1.3–2 hours of in-
gestion [67, 68]. Once in the bloodstream, ticagrelor does
not require hepatic transformation as it already exists as a
pharmacologically active compound. There are ten metabo-
lites of ticagrelor [46]. The predominant active metabolite is
AR-C124910XX (ticagrelor active metabolite, TAM; Fig. 2),
a product of the cytochromeP450 (CYP)3A4/5 enzymes [69],
which reaches peak plasma concentration (Cmax) in 1.5–3
hours (tmax). The peak plasma concentrations of TAM are
approximately 30% of the parent compound. Ticagrelor ex-
hibits linear and predictable pharmacokinetics with single
oral doses up to 400 mg and multiple doses up to 300 mg
twice daily (BD): the Cmax and area under the curve (AUC)
of ticagrelor and its active metabolite increase in a dose-
dependent manner, while the tmax, terminal phase half-life
(t1/2)and plasma oral clearance are independent of the dose.
These findings are broadly consistent in healthy participants
[67, 68] and patients with stable CAD [70] or ACS [71]. The
majority of ticagrelor and its metabolites are excreted via the
biliary and intestinal system, while there is minor renal in-
volvement [46]. The mean t1/2 of ticagrelor and its active
metabolite in healthy subjects are 7.1–8.5 hours and 8.5–10.1
hours, respectively [68].
There are several clinically significant pharmacologi-
cal interactions between ticagrelor and other medications.
While ticagrelor is primarily a substrate of CYP3A4, it also
mildly inhibits the same isozyme [72], and therefore co-
administration with CYP3A4 substrates with a narrow ther-
apeutic index (e.g., ergot alkaloids) is discouraged due to an
increased risk of elevated exposure [73]. In addition, strong
CYP3A4 inhibitors (e.g., ketoconazole and clarithromycin)
are contraindicated since they potentially lead to excessive
ticagrelor levels and strong CYP3A inducers (e.g., phenytoin
and carbamazepine) are discouraged since they may risk sub-
therapeutic ticagrelor levels [50, 73]. With greater relevance
to cardiovascular disease, the Cmax and AUC of simvastatin
80 mg (also a CYP3A substrate) is increased by 81% and 56%
respectivelywhen co-administeredwith ticagrelor [74]. Sim-
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vastatin doses greater than 40 mg therefore should not be co-
prescribed with ticagrelor [73]. Encouragingly, there was no
increase in statin-related adverse reactions reported in the
90% of patients in the PLATO study who received both a
statin and ticagrelor [12].
Ticagrelor is also a substrate and inhibitor of the intesti-
nal P-glycoprotein transporter and administration of tica-
grelor during treatment with digoxin (a P-glycoprotein sub-
strate) led to 75% and 28% increases in the Cmax and AUC
of digoxin, respectively [75]. Therefore, the combination re-
quires appropriate monitoring to avoid digoxin toxicity [73].
Various studies have identified that the administration of
morphine delays the absorption and onset of action of oral
P2Y12 inhibitors [76–79]. Opioid receptor agonists are asso-
ciated with a marked delay in gastric emptying and intestinal
absorption [80]; since oral P2Y12 inhibitors are almost exclu-
sively absorbed in the intestine [46], their absorption can be
delayed for hours by opiates. This effect is particularly im-
portant to consider when aspirin and an oral P2Y12 inhibitor
such as ticagrelor are required to prevent acute stent throm-
bosis, with potentially catastrophic consequences [81–83]. In
these patients, administration of a parenteral antithrombotic
drug to cover the delayed absorption may reduce the risk of
acute stent thrombosis, such as a 6-hour infusion of the glyco-
protein IIb/IIIa antagonist tirofiban [84], the low-molecular-
weight heparin enoxaparin [85, 86] or the intravenous P2Y12
inhibitor cangrelor [87].
There is currently no evidence that the pharmacoge-
netic profile of ticagrelor impacts the clinical outcome
in patients with ACS. In a genome-wide association
study, three single-nucleotide polymorphisms were iden-
tified (SLCO1B1, UGT2B7, CYP3A4) that influenced the
pharmacokinetics of ticagrelor and its active metabolite, but
not to an extent that interfered with the safety or efficacy
of the regimen [88]. In addition, common variations in the
ENT1 genotype are not associated with altered clinical out-
comes following the administration of ticagrelor or clopido-
grel [89].
5. Pharmacodynamics of ticagrelor
Both ticagrelor and clopidogrel arewidely used oral P2Y12
inhibitors; however, there are a few important differences
that highlight favourable characteristics of ticagrelor in the
context of clinical practice.
As a feature of thienopyridines, clopidogrel irreversibly
antagonises P2Y12 receptors for the duration of the platelet’s
lifespan, which is approximately seven-to-ten days [90]. The
implication of this is that, if urgent surgery is required in
a patient taking clopidogrel, there is an increased risk of
life-threatening bleeding if insufficient time elapses between
drug cessation and surgery [91], particularly in those who
are high responders to clopidogrel [92]. Thienopyridines are
prodrugs that require hepatic transformation into pharma-
cologically active compounds by CYP isozymes. The for-
mation of the active metabolite of clopidogrel is a two-step
CYP-mediated process and, therefore, is susceptible to inter-
individual variation in CYP activity, in particular that of
CYP2C19, as well as various other factors [93–96]. This may
be an important contributing factor to clopidogrel resistance,
which leaves approximately 30% of patients susceptible to ad-
verse cardiovascular events [97–101].
Unlike thienopyridines, ticagrelor binds reversibly to
P2Y12, resulting in declining levels of platelet inhibition
from 24 hours after cessation, but also provides adequate
platelet inhibition if a single dose is missed since the subse-
quent maintenance dose is sufficient to restore a high level
of platelet inhibition [71, 102]. Because ticagrelor’s chem-
ical structure enables it to directly interact with the P2Y12
receptor without requiring metabolism, the peak inhibition
of platelet aggregation is achieved rapidly, with high lev-
els of inhibition achieved within 30 minutes and reaching
peak within 2 hours of a single dose in stable patients [102],
in comparison to clopidogrel, which can take 4–8 days us-
ing a conventional maintenance dose or 4–6 hours after a
high loading dose (600 mg) [103, 104]. The rapid onset and
offset of ticagrelor are desirable qualities of an antiplatelet
agent that provide greater flexibility in clinical practice. Fur-
thermore, ticagrelor and its active metabolite, with equiva-
lent potency [46], appear to provide consistent platelet in-
hibition at mean levels that are greater than with either
clopidogrel, even in those who are most responsive to it
[50, 102, 105, 106], or prasugrel during maintenance ther-
apy [107]. Further work is required to determine if this is a
result of pure potency or whether other mechanisms, includ-
ing inverse agonism, are responsible. At steady state, tica-
grelor is constantly present in the blood, resulting in inhibi-
tion of newly-produced platelets [71]. The concentration of
ticagrelor in the plasma during long-termmaintenance treat-
ment with 60 mg or 90 mg BD is sufficient to achieve high
levels of inhibition of platelet aggregation in patients with a
previous MI [108], stable CAD undergoing PCI [50] or di-
abetes mellitus [109]. The sustained levels of platelet inhi-
bition are greater when ticagrelor is administered BD rather
than once daily (OD) [67].
To achieve acceptable outcomes, the antithrombotic ef-
ficacy must be balanced against the risk of bleeding and
therefore a pharmacological agent that is capable of revers-
ing the haemostatic effects of ticagrelor is highly desirable
for use in emergency procedures where the risk of bleed-
ing is increased. Bentracimab (PB2452) is an antigen-binding
fragment antidote to ticagrelor that has demonstrated effec-
tive neutralisation properties both in vitro and in mice [110]
and healthy volunteers [111]. A numerical improvement in
ADP-induced platelet aggregation, blood loss and survival
in response to PB2452 in pigs provides further encourage-
ment [112], and pharmacological characterisation [113] and
phase IIB and phase III studies are underway (ClinicalTri-
als.gov Identifier: NCT04122170 and NCT04286438 respec-
tively). An alternative approach in patients undergoing ur-
gent or emergency cardiopulmonary bypass surgery or ex-
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tracorporeal membrane oxygenation is reducing ticagrelor
plasma levels using haemadsorption with the CytoSorb car-
tridge system that can be linked with the bypass circuit and is
CE-marked for this purpose [114] (ClinicalTrials.gov Identi-
fier: NCT04131959).
6. Clinical outcomes in phase II studies
The Dose confIrmation Study assessing anti-Platelet Ef-
fects of AZD6140 vs. clopidogRel in non-ST-segment Eleva-
tion myocardial infarction (DISPERSE)-2 study investigated
the safety, tolerability and initial efficacy of two doses of tica-
grelor (90 mg or 180 mg BD) plus aspirin, compared with
standard clopidogrel (300mg loading dose, 75mgOD)DAPT
in 984 patients with NSTE-ACS [115]. There was no differ-
ence in the incidence of overall bleeding at 4weeks (ticagrelor
90 mg, 180 mg and clopidogrel; 9.8%, 8.0% and 8.1% respec-
tively; P = 0.43 and P = 0.96, respectively, vs. clopidogrel)
between the groups. The results also suggested good toler-
ability of ticagrelor, but showed a higher incidence of dysp-
noea (10.5%, 15.8% and 6.4%; P = 0.07 and P < 0.001) and
asymptomatic ventricular pauses >2.5 seconds (5.5%, 9.9%
and 4.3%; P = 0.58 and P = 0.014), in a dose-dependent pat-
tern, compared with clopidogrel. Encouragingly, there were
numerically lower rates of MACE and bleeding after cessa-
tion for patients who required a coronary artery bypass graft
(CABG). These findings paved the way for large-scale trials
to further characterise the efficacy and safety of ticagrelor in
the management of MI.
7. Phase III studies of ticagrelor in coronary
artery disease
As a result of a worldwide collaborative effort, studies
have highlighted the benefits of using ticagrelor-basedDAPT
for the secondary prevention of MACE in ACS patients, up
to one year and beyond, in post-ACS patients at high risk of
ischaemic events.
18,624 patients with ACS were recruited to the double-
blind randomised Platelet Inhibition and Patient Outcomes
(PLATO) study to compare the efficacy of ticagrelor and
clopidogrel, administered with aspirin [12]. Ticagrelor not
only proved superior at reducing the primary composite end-
point of vascular death, MI and stroke at 12 months (9.8%
[ticagrelor] vs. 11.7% [clopidogrel]; HR, 0.84; 95% CI 0.77–
0.92; P < 0.001; Table 1), but also cardiovascular mortal-
ity (4.0% vs. 5.1%; P = 0.001) and all-cause mortality (4.5%
vs. 5.9%; P < 0.001). The study identified no statistically-
significant difference in the rates of major bleeding (11.6%
vs. 11.2%; HR, 1.04; 95% CI 0.95–1.13; P = 0.43) or CABG-
related bleeding (7.4% vs. 7.9%; HR, 0.95; 95% CI 0.85–1.06;
P = 0.32). This may be explained by the shorter biological
t1/2 of ticagrelor, despite having greater potency, whereby
cessation prior to a procedure results in a quicker recovery to
normal platelet function than clopidogrel. There was an ele-
vated risk of spontaneous bleeding (4.5% vs. 3.8%; HR, 1.19;
95% CI 1.02–1.38; P = 0.03), including an increase in fatal
intracranial bleeding (0.12% vs. 0.01%; P = 0.02) in the tica-
grelor group. However, overall rates of fatal bleeding were
not significantly different due to more non-intracranial fatal
bleeds when receiving clopidogrel. The PLATO study was
the first to show that more potent platelet inhibition with
ticagrelor versus clopidogrel translated to improved overall
clinical outcomes.
Before the Prevention of Cardiovascular Events in Pa-
tients with Prior Heart Attack Using Ticagrelor Compared
to Placebo on a Background of Aspirin (PEGASUS-) Throm-
bolysis in Myocardial Infarction (TIMI) 54 study, it was un-
clear if DAPT should be carried on beyond 12 months post-
MI for patients at high risk of developing further ischaemic
events [13, 116]. This prospective study investigated the ef-
ficacy of two doses of ticagrelor versus placebo, combined
with low-dose aspirin, over a 3-year period in 21,126 stable
patients with a history of MI (median 1.7 years prior), who
were at least 50 years old and had an additional atherothrom-
botic risk factor (Table 1). Ticagrelor was studied for the first
time at a dose of 60 mg BD in addition to further study of the
90 mg BD dose. Both ticagrelor doses significantly reduced
the incidence of MACE (7.9% [ticagrelor 90 mg], 7.8% [tica-
grelor 60 mg] and 9.0% [placebo]; P = 0.008 and P = 0.004
vs. placebo, respectively). Cardiovascular deaths alone were
not significantly reduced versus placebo in the overall trial
population although there was evidence of a reduced risk of
CAD-related deaths (90 mg: HR, 0.73 [95% CI 0.56–0.95];
60 mg: HR, 0.80 [95% CI 0.62–1.04]). Ticagrelor increased
the incidence of major (2.6%, 2.3% and 1.1%; P < 0.001 for
both) and minor bleeding, but there was no significant dif-
ference in fatal bleeding versus placebo. A subgroup analysis
of the PEGASUS-TIMI 54 study identified a greater absolute
risk reduction of MACE in patients with type 2 diabetes mel-
litus (T2DM) who received ticagrelor-based DAPT (1.5% vs.
1.1%) than those without [117]. The novel 60 mg dose of
ticagrelor was chosen for this study to provide an interme-
diate level of antithrombotic protection, that would provide
greater antithrombotic efficacy than clopidogrel 75 mg, but
less of a bleeding risk than ticagrelor 90 mg [118]. Surpris-
ingly, both doses of ticagrelor demonstrated similar overall
efficacy at preventing ischaemic events, which was explored
in a pharmacodynamic study that demonstrated similar mag-
nitude of platelet inhibition at both doses [108]. The rates
of bleeding, dyspnoea and discontinuation as a result of dys-
pnoea were numerically lower in the ticagrelor 60 mg group
versus 90 mg. Therefore, in view of a similar efficacy and
safety profile with better tolerability, this evidence suggests
that ticagrelor 60 mg BD may be a more favourable option
to 90 mg BD when combined with aspirin during long-term
DAPT. Overall, the PEGASUS-TIMI 54 trial demonstrated
that, for patients at high risk of recurrent ischaemic events, a
longer duration of DAPT may derive benefit, but this needs
to beweighed against the higher risk of non-fatal bleeding. In
selecting those most likely to benefit from long-term DAPT,
further subgroup analysis of PEGASUS-TIMI 54 supported
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Table 1. Randomised clinical trials of ticagrelor-based dual antiplatelet therapy for secondary prevention in patients with atherosclerotic disease.
Short name
(year published)
Study population Intervention Comparator Primary endpoint(s) Key safety endpoint(s)
PLATO (2009)
[12]
18,624 patients hospitalised with ACS Ticagrelor (180 mg LD, 90 mg
BDMD) plus aspirin 75–325mg
OD for 12 months
Clopidogrel (300–600 mg LD,
75 mg MD) plus aspirin 75–325
mg OD for 12 months
Death from vascular cause, MI or stroke at 12
months: 9.8% vs. 11.7%; Hazard ratio (HR),
0.84; 95% confidence interval (CI) 0.77–0.92;
P < 0.001
Major bleeding at 12months: 11.6% vs. 11.2%; HR,
1.04; 95% CI 0.95–1.13; P = 0.43
PEGASUS-TIMI
54 (2015) [13]
21,162 patients with prior spontaneous
MI in the last 1–3 years and an additional
atherothrombotic risk factor*
Ticagrelor 90 mg (T90) or 60
mg (T60) BD plus aspirin 75–
150 mg OD for 36 months
Placebo plus aspirin 75–150
mg OD for 36 months
CV death, MI, or stroke at 3 years: TIMI major bleeding at 3 years:
T90: 7.9% vs. 9.0%; HR, 0.85; 95% CI 0.75–
0.96; P = 0.008
T90: 2.6% vs. 1.1%; HR, 2.69; 95% CI 1.96–3.70; P
< 0.001
T60: 7.8% vs. 9.0%; HR, 0.84; 95% CI 0.74–
0.95; P = 0.004




500 patients with an indication for
elective coronary artery bypass graft
surgery. 1460 saphenous vein grafts
were inserted
Ticagrelor 90 mg BD plus
aspirin (100 mg OD) or alone
for 1 year
Aspirin 100 mg OD for 1
year
Graft patency at 1 year: DAPT: 88.7% vs.
76.5%; RR, 0.48; 95% CI 0.31–0.74; P < 0.001
Graft patency at 7 days: DAPT: 94.9% vs. 91.1%;
RR, 0.58; 95% CI 0.30–1.14; P = 0.11
Ticagrelor alone: 82.8% vs. 76.5%; RR, 0.73,
95% CI 0.51–1.06; P = 0.10
Ticagrelor alone: 94.3% vs. 91.1%; RR, 0.65, 95%
CI 0.36–1.18; P = 0.17
ISAR-REACT 5
(2019) [15]
4018 patients hospitalised with ACS for
whom an invasive evaluation was sched-
uled. Treatment: 84% PCI and 2.1%
CABG
Ticagrelor (180 mg LD, 90 mg
BD MD) based strategy for 12
months
Prasugrel (60 mg LD, 10 mg or
5 mg (if ≥75 years or <60 kg)
OD MD) based strategy for 12
months
Death, MI or stroke at 1 year: 9.3% vs. 6.9%;
HR, 1.36; 95% CI 1.09–1.70; P = 0.006
Bleeding Academic Research Consortium (BARC)
type 3, 4, or 5 bleeding at 1 year: 5.4% vs. 4.8%;
HR, 1.12; 95% CI 0.83–1.51; P = 0.46
THEMIS (2019)
[16]
19,220 patients with stable CAD, type 2
diabetes and no prior MI or stroke
Ticagrelor (90 mg initially, then
reduced to 60 mg) BD plus as-
pirin 75–150 mg OD for 54
months
Placebo plus aspirin 75–150 mg
OD for 54 months
CV death, MI, or stroke: 7.7% vs. 8.5%; HR,
0.90; 95% CI 0.81–0.99; P = 0.04
TIMImajor bleeding: 2.2% vs. 1.0%; HR, 2.32; 95%
CI 1.82–2.94; P < 0.001
THALES (2020)
[17]
11,016 patients with acute non-
cardioembolic, non-severe ischaemic
stroke (National Institutes of Health
Stroke Score (NIHSS) ≤5) or high-risk
transient ischemic attack (ABCD2 ≥6)
or symptomatic arterial stenosis
Ticagrelor (180 mg LD, 90 mg
BD MD) plus aspirin (300–325
mg LD, 75–100mgODMD) for
34 days
Placebo plus aspirin (300–325
mg LD, 75–100mgODMD) for
34 days
Stroke or death at 30 days: 5.5% vs. 6.6%; HR,
0.83; 95% CI 0.71–0.96; P = 0.02
GUSTO severe bleeding at 30 days: 0.5% vs. 0.1%;
HR, 3.99; 95% CI 1.74–9.14; P = 0.001
ALPHEUS (2020)
[18]
1910 patients with stable CAD with an
indication for PCI and at least 1
high-risk feature†
Ticagrelor (180 mg LD, 90 mg
BDMD) (87% on aspirin
at admission) for 30 days
Clopidogrel (300–600 mg
LD, 75 mg ODMD) (85% on
aspirin at admission) for
30 days
PCI-related type 4 (a or b) MI or major
myocardial injury at 48 h: 35% vs. 36%;
OR, 0.97; 95% CI 0.80–1.17;
P = 0.75
Major bleeding (BARC 3 or 5) at 48 h: <1% vs. 0%;
P = 0.50
Minor bleeding (BARC 1 or 2) at 30 days: 11% vs.
8%; OR, 1.54; 95% CI 1.12–2.11; P = 0.007
* One of the following: ≥65 years old, diabetes treated with medication, a second prior spontaneous MI, multivessel CAD, chronic renal dysfunction (estimated creatinine clearance<60 mL per minute).
†≥75 years old, renal insufficiency (clearance<60 mL per minute), diabetes mellitus, overweight (BMI>30 kg/m2), history of ACS in last year, left ventricular ejection fraction<40% and/or prior episode of heart failure,






the approach of excluding patients with anaemia or a his-
tory of prior hospitalisation in addition to the exclusion cri-
teria for the trial related to bleeding, such as prior ischaemic
or haemorrhagic stroke [119]. This analysis suggested sig-
nificant cardiovascular mortality reduction from long-term
DAPT in the patients with higher ischaemic risk and with-
out high-bleeding-risk characteristics whereas those with
anaemia or prior hospitalisation for bleeding did not appear
to benefit.
In response to the publication of the PEGASUS-TIMI 54
study, all active or newly-enrolled participants in The Ef-
fect of Ticagrelor on Health Outcomes in Diabetes Mellitus
Patients Intervention Study (THEMIS) [16] were switched
to or started on, respectively, the lower dose of ticagrelor
(60 mg BD). Primary and supplementary analysis showed
consistent results independent of the dose. THEMIS was
a randomised double-blind trial that sought to determine if
adding ticagrelor to aspirin improves outcomes in patients
with stable CAD and T2DMwith no history of MI or stroke.
The results showed that addition of ticagrelor to aspirin re-
duced the incidence of MACE (7.7% [ticagrelor] vs. 8.5%
[placebo]; HR, 0.90; 95% CI 0.81–0.99; P = 0.04) but con-
versely increased major bleeding (2.2% vs. 1.0%; HR, 2.32;
95% CI 1.82–2.94; P < 0.001), after a median follow-up of 40
months. In an exploratory analysis featuring a composite of
irreversible and harmful outcomes (all-cause mortality, MI,
stroke, fatal bleeding or intracranial haemorrhage), there was
no significant difference between the ticagrelor and placebo
treatment groups (10.1% vs. 10.8%; HR, 0.93; 95% CI 0.86–
1.02), leading the authors to conclude that ticagrelor plus as-
pirin may not be an acceptable form of secondary preven-
tion of ischaemic events in this population, due to the poor
benefit-to-risk ratio. However, the evidence supported the
extension of the US label for ticagrelor to include stable pa-
tients at high risk of ischaemic events, including those with-
out diabetes.
The Intracoronary Stenting and Antithrombotic Regi-
men: Rapid Early Action for Coronary Treatment (ISAR-
REACT) 5 trial was a recent open-label randomised con-
trolled trial (RCT) that compared two different treatment
strategies in 4018 patients with ACS who were scheduled for
invasive evaluation (i.e., coronary angiography) [15]. Fol-
lowing randomisation, a loading dose of ticagrelor was im-
mediately administered to all patients randomised to tica-
grelor whereas only STEMI patients randomised to prasugrel
were intended to receive the loading dose of prasugrel be-
fore coronary angiography and those with NSTE-ACS un-
derwent coronary angiography first, following which they
received a loading dose of prasugrel only if proceeding to
PCI, reflecting the evidence that prasugrel increases the risk
of major bleeding if administered pre-PCI in this popula-
tion [120]. ISAR-REACT 5 found that the ticagrelor-based
strategy was less effective at preventing MACE (9.3% [tica-
grelor] vs. 6.9% [prasugrel]; HR, 1.36; 95% CI 1.09–1.70; P
= 0.006) compared to the prasugrel-based strategy and that
there was no difference in major bleeding (5.4% vs. 4.8%;
HR, 1.12; 95% CI 0.83–1.51; P = 0.46) after one year. This
finding was unexpected as the trial was testing the hypothe-
sis that ticagrelor would be superior to prasugrel. In addition
to the open-label design of the study, there were a number
of considerations that indicate the need for caution in trans-
lating the findings to clinical practice: (1) patients were ran-
domised within 1–2 hours of coronary angiography and so
any benefit of ticagrelor pre-treatment in patients waiting
longer for coronary angiography was not assessed; (2) the
majority of patients had femoral artery access for their proce-
dure, which does not reflect contemporary optimal practice
and would have disadvantaged the pre-treatment approach
with ticagrelor; (3) approximately one-third of the benefit of
prasugrel was through reduction in stent thrombosis, which
is not consistent with the platelet inhibition profiles of the
two drugs and therefore likely indicates poor adherence in
the ticagrelor group, raising questions about the counselling
and management of the study patients since better outcomes
have been achieved in experienced centres; and (4) the bet-
ter outcomes with prasugrel also partly reflected lower non-
cardiovascular mortality, which is inconsistent with the re-
sults of the much larger phase-III studies and therefore sug-
gests the play of chance. Poor adherence may have been a
particular issue in the patients without diabetes since patients
with diabetes did equally well with the ticagrelor-based and
prasugrel-based strategies in the trial [121]. Large-scale ob-
servational data indicate similar outcomeswith ticagrelor and
prasugrel in PCI-treated MI patients [122, 123]. Reports of
greater platelet inhibitionwith prasugrel comparedwith tica-
grelor maintenance therapy are likely based on artefact re-
lated to the use ofmultiple electrode plate aggregometry since
studies with other platelet function tests have demonstrated
greater platelet inhibition during maintenance therapy with
ticagrelor [107, 124] and this is consistent with the different
development strategies for the two drugs [123].
8. Studies of ticagrelor in percutaneous
coronary intervention
PCI is a procedure frequently performed in patients with
CAD, usually involving the insertion of at least one drug-
eluting stent (DES) to treat and prevent the progression of
focal coronary artery stenosis. Approximately 60% of ACS
patients undergo PCI when hospitalised [12]. A range of in-
novative studies involving ticagrelor have recently been con-
ducted with the aim to optimise patient outcomes by reduc-
ing the burden of ischaemia and/or bleeding for those who
have received PCI by tailoring the duration and combination
of antiplatelet drugs.
Twometa-analyses [125, 126] collated ten RCTs to deter-
mine the length of time that DAPT should be administered
following DES insertion during PCI. They both favoured a
shorter duration of DAPT (<12 months) over long term
(>12months) therapy, based on the finding that a longer du-
ration of DAPT was associated with higher rates of bleeding
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complications and all-cause mortality, despite a reduction in
MI and stent thrombosis. As these studies mainly involved
thienopyridine-based DAPT, these data cannot be extrapo-
lated to how ticagrelor may perform. Moreover, there is evi-
dence to suggest that prolonged ticagrelor-based DAPT may
benefit a specific high-risk subset of patients.
A prespecified subgroup analysis of the THEMIS study
(median follow-up of 3.3 years) demonstrated an improved
benefit-to-risk ratio for ticagrelor in patients with a PCI pro-
cedure in the past [127]. In this subgroup, there was a lower
rate of both MACE (7.3% [ticagrelor] vs. 8.6% [placebo];
HR, 0.85; 95% CI 0.74–0.97; P = 0.013) and the exploratory
net clinical benefit endpoint of irreversible harms (9.3% vs.
11.0%; HR, 0.85; 95% CI 0.75–0.95; P = 0.005), involving
a composite of all-cause mortality, MI, stroke, fatal bleed-
ing or intracranial haemorrhage. In contrast, patients with
no history of PCI appeared to obtain no net clinical benefit
from ticagrelor based-DAPT according to the latter compos-
ite endpoint (11.1% vs. 10.5%; HR, 1.06; 95% CI 0.93–1.21; P
= 0.39). TIMI-defined major bleeding was significantly more
frequent when receiving ticagrelor regardless of whether or
not the patient had a history of PCI (2.0% vs. 1.1%; HR, 2.03;
95% CI 1.48–2.76; P < 0.001). Those specifically with a his-
tory of PCI, including implantation of a DES, appeared to de-
rive an even greater reduction in MACE (6.9% vs. 8.6%; HR,
0.79; 95% CI 0.67–0.94; P = 0.008). This evidence raised the
hypothesis that the addition of ticagrelor to aspirin reduces
the risk of MACE in patients with stable CAD, T2DM and a
history of PCI, especially with a DES, but not in those who do
not have a history of PCI. However, the reasons for a selective
effect in the PCI subgroup are unclear although prior toler-
ance of DAPT following PCI might explain the preferential
efficacy.
Considering that increasing the efficacy of antiplatelet
regimens is accompanied by a penalty in bleeding risk, an-
other novel strategy that has gained attention is the discon-
tinuation of aspirin, after a short period of DAPT, at an early
stage after PCI (Table 2). While de-escalating antiplatelet
therapy is unlikely to reduce ischaemic risk, it may improve
safety yet maintain efficacy. This may be particularly impor-
tant in the context of severe post-PCI bleeding, which poses
a similar mortality risk compared with MI [128, 129].
The Clinical Study Comparing Two Forms of Anti-
platelet Therapy After Stent Implantation (GLOBAL LEAD-
ERS) study sought to determine if ticagrelor-based DAPT for
one month followed by ticagrelor monotherapy was superior
to standard DAPT therapy (aspirin plus either ticagrelor for
ACS or clopidogrel for CCS) for 12 months followed by as-
pirin monotherapy, over a two-year period following DES
implantation in 15,968 patients [21]. The findings demon-
strated no difference in the ambitious primary composite
endpoint of all-causemortality or newQ-waveMI (3.81% [1-
month DAPT] vs. 4.37% [12-month DAPT]; risk ratio [RR],
0.87; 95% CI 0.75–1.01; P = 0.073) or the key safety end-
point of major bleeding (2.04% vs. 2.12%; RR, 0.97; 95% CI
0.78–1.20; P = 0.77). In a recent post-hoc subgroup analysis of
the ACS cohort that evaluated clinical outcomes between 31
and 365 days post-randomisation, thereby exclusively com-
paring ticagrelor monotherapy with ticagrelor-based DAPT,
there remained no significant difference in the primary end-
point (1.5% [monotherapy] vs. 2.0% [DAPT]; HR, 0.73; 95%
CI 0.51–1.03; P = 0.073) but a significant reduction in ma-
jor bleeding was observed (0.8% vs. 1.5%; HR, 0.52; 95% CI
0.33–0.81; P = 0.004) [130]. While the results of this analy-
sis are encouraging, they must be considered as hypothesis-
generating in light of their post-hoc nature, although the re-
duction in bleeding with aspirin cessation is predictable due
to the subsequent increase in platelet reactivity and avoidance
of aspirin-related gastrotoxicity [131].
Furthermore, in the Ticagrelor with Aspirin or Alone
in High-Risk Patients after Coronary Intervention (TWI-
LIGHT) study, 9006 patients who were determined to be at
high risk of bleeding or ischaemia received DAPT with tica-
grelor and aspirin for three months following PCI with DES
for NSTE-ACS (65%) or CCS (35%) [22]. Of those who did
not suffer from a disqualifying event, 7119 continued to take
ticagrelor and were randomised to either receive placebo or
continue with aspirin for a duration of 12 months. Reflect-
ing the priority of the experimental regimen to provide a
better safety profile than the standard-treatment compara-
tor while maintaining safe antithrombotic protection, the
primary endpoint was a composite of BARC (Bleeding Aca-
demic Research Consortium)-defined grade 2, 3 or 5 bleed-
ing and the key secondary endpoint was a composite of all-
causemortality, non-fatalMI or non-fatal stroke. The results
showed that the primary endpoint occurred significantly less
frequently during ticagrelor monotherapy than DAPT (4.0%
[monotherapy] vs. 7.1% [DAPT]; HR, 0.56; 95% CI 0.45–
0.68; P < 0.001) without evidence for a difference in the key
secondary endpoint (3.9% vs. 3.9%; HR, 0.99; 95% CI 0.78–
1.25; P (noninferiority) < 0.001). The results suggest that
DAPT for three months may be sufficient to cover the pe-
riod of stent endothelialisation and stent thrombosis risk but
there remains uncertainty in view of limited power of this
study to assess the efficacy of the regimens in individuals at
high long-term risk of ischaemic events.
In a pre-specified subgroup analysis, TWILIGHT-ACS
highlighted that ticagrelor monotherapy provided greater
magnitude of reduced bleeding in 4614 patients with NSTE-
ACS (3.6% [monotherapy] vs. 7.6% [DAPT]; HR, 0.47; 95%
CI 0.36–0.61; P < 0.001) than those with CCS (4.8% vs. 6.2%;
HR, 0.76; 95% CI 0.54–1.06; P = 0.11; nominal Pinteraction =
0.03), while the risk ofMACEwas similar for both treatment
groups and independent of the clinical presentation [132]. In
support of these findings, but in a low-risk population, the
Ticagrelor Monotherapy After three Months in the Patients
Treated With New Generation Sirolimus-eluting Stent for
ACS (TICO) study demonstrated that switching to ticagrelor
monotherapy after three months of DAPT significantly re-
duced the frequency of the composite primary endpoint
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Table 2. Randomised clinical trials of ticagrelor monotherapy for secondary prevention in patients with atherosclerotic disease.
Short name
(year published)
Study population Intervention Comparator Primary endpoint(s) Key safety endpoint(s)
SOCRATES
(2016) [19]
13,199 patients with acute, non-
cardioembolic, non-severe ischaemic
stroke (NIHSS ≤5) or high-risk TIA
(ABCD2 ≥4)
Ticagrelor (180 mg LD, 90 mg
BDMD)plus placebo for 90 days
Aspirin (300 mg LD, 100 mg OD
MD) plus placebo for 90 days
Ischaemic or haemorrhagic stroke, MI
or death at 90 days: 6.7% vs. 7.5%; HR,
0.89; 95% CI 0.78–1.01; P = 0.07
PLATO major bleeding at 90 days: 0.5% vs.
0.6%; HR, 0.83; 95% CI 0.52–1.34; P = 0.45
EUCLID (2017)
[20]
13,885 patients with either previous
revascularisation of lower limbs or
haemodynamic evidence due to
symptomatic PAD
Ticagrelor 90 mg BD for
36 months
Clopidogrel 75 mg OD for
36 months
CV death, MI or ischaemic stroke: 10.8%
vs. 10.6%; HR, 1.02; 95% CI 0.92–1.13;
P = 0.65
TIMImajor bleeding: 1.6% vs. 1.6%; HR, 1.10;
95% CI 0.84–1.43; P = 0.49
TIMI minor bleeding: 1.2% vs. 1.0%; HR,




15,968 patients receiving a DES for stable
CAD (53.1%) or ACS (46.9%), between
angiography and PCI
Aspirin 75–100 mg OD plus
ticagrelor 90 mg BD for 1
month, followed by ticagrelor
90mg BD for 23 months
Aspirin 75–100 mg plus either clopi-
dogrel 75mg OD (stable CAD) or
ticagrelor 90mg BD (ACS) for 12
months, then aspirin for 12 months
All-cause mortality or new Q-wave MI
at 730 days: 3.81% vs. 4.37%; RR, 0.87;
95% CI 0.75–1.01; P = 0.073
BARC grade 3 or 5 bleeding: 2.04% vs. 2.12%;
RR, 0.97; 95% CI 0.78–1.20; P = 0.77
TWILIGHT
(2019) [22]
7119 high-risk patients* who underwent
PCI for either stable CAD or NSTE-ACS,
and 3 event-free months of ticagrelor 90
mg BD plus aspirin 81–100 mg OD
Ticagrelor 90 mg BD plus
placebo for 12 months
Aspirin 81–100 mg OD plus tica-
grelor 90 mg BD for 12 months
BARC grade 2, 3 or 5 bleeding at 1 year:
4.0% vs. 7.1%; HR, 0.56; 95% CI 0.45–
0.68; P < 0.001
All-cause mortality, non-fatal MI or non-fatal
stroke at 1 year: 3.9% vs. 3.9%; HR, 0.99; 95%
CI 0.78–1.25; P (noninferiority)< 0.001
TICO (2020)
[23]
3065 patients treated with DES for ACS
Aspirin 100 mg OD plus
ticagrelor 90 mg BD for 3
months, then ticagrelor 90
mg BD for 9 months
Aspirin 100 mg OD plus
ticagrelor 90 mg BD for
12 months
Net adverse clinical events† at 12
months: 3.9% vs. 5.9%; HR, 0.66; 95%
CI 0.48–0.92; P = 0.01
TIMI major bleeding at 12 months: 1.7% vs.
3.0%; HR, 0.56; 95% CI 0.34–0.91; P = 0.02
MACE at 12 months: 2.3% vs. 3.4%; HR, 0.69;
95% CI 0.45–1.06; P = 0.09
* At least one additional clinical (at least 65 years old, female gender, troponin positive ACS, established vascular disease, diabetes treated with medication, CKD) and one angiographic (multivessel CAD, total stent length
>30 mm, a thrombotic target lesion, bifurcation lesion treated with two stents, obstructive left main or proximal left anterior descending lesion, a calcified target lesion treated with atherectomy) feature.






(TIMI major bleeding and major cardiac and cerebrovas-
cular events [death, MI, stent thrombosis, stroke or target
vessel revascularisation]; 3.9% [3-month DAPT] vs. 5.9%
[12-month DAPT]; HR, 0.66; 95% CI 0.48–0.92; P = 0.01)
compared with continuing DAPT for 12 months (n = 3065)
[23]. The key secondary endpoints indicated a reduced risk
of TIMI-major bleeding (1.7% vs. 3.0%; HR, 0.56; 95% CI
0.34–0.91; P = 0.02) and no significant difference in MACE
(2.3% vs. 3.4%; HR, 0.69; 95% CI 0.45–1.06; P = 0.09). No-
tably, however, there are several important limitations of this
recent study, which was open-label, did not monitor drug
adherence, involved study sites that were exclusively based
in South Korea and excluded any participants who were de-
termined to be at high risk of bleeding. The collective evi-
dence suggests that ticagrelor monotherapy has potential ad-
vantages over standard treatments following PCI and will be
discussed in a subsequent section of this review.
Considering the evidence, it is becoming increasingly ap-
parent that a tailored approach is required for ticagrelor-
treated patients, particularly thosewithACS.While theman-
agement of modifiable risk factors and development of thin-
strut, biocompatible DES is improving clinical outcomes [8,
133], current evidence suggests the need for a dichotomiza-
tion of treatment whereby those with unmodifiable risk fac-
tors for atherothrombotic events, but with a low risk of
bleeding, receive long-term DAPT and those with control-
lable risk factors or a high risk of bleeding receive ticagrelor
monotherapy following short-term DAPT [134].
Ticagrelor may not provide benefit in low-risk indi-
viduals undergoing elective PCI. With the aim to re-
duce prognostically-important periprocedural myonecrosis
[135], the recently-published Assessment of Loading with
the P2Y12 inhibitor ticagrelor or clopidogrel to Halt is-
chaemic Events in patients Undergoing elective coronary
Stenting (ALPHEUS) open-label study reported that tica-
grelor showed no superiority over clopidogrel at preventing
periprocedural MI or myocardial injury (35% [ticagrelor] vs.
36% [clopidogrel]; odds ratio [OR], 0.97; 95% CI 0.80–1.17;
P = 0.75) within 48 hours of elective PCI in 1910 high-risk
patients [18]. A similar lack of effect on periprocedural my-
onecrosis was also observed in a small study of elective PCI
patients comparing ticagrelor 90 mg or 60mg BDwith clopi-
dogrel [50]. Considering that ticagrelor showed no superior-
ity over clopidogrel, despite greater potency of platelet inhi-
bition, these studies suggest that much of the periprocedural
myonecrosis in low-risk PCI patients occurs independently
of platelet activation, such as due to embolisation of plaque
contents into the coronary microcirculation.
9. Ticagrelor in ST-elevationmyocardial
infarction
The severity of ischaemia during STEMI and the suscep-
tibility to further infarction of adjacent myocardial tissues
makes it a particularly time-sensitive event, whereby the op-
timal choice of agent and timing requires careful consider-
ation and elaboration. In a PLATO subgroup of patients
with STEMI or left bundle branch block planned for primary
PCI, ticagrelor remained superior to clopidogrel at prevent-
ingMACE at 12months [136]. This benefit was independent
of the extent of ST elevation at presentation and ticagrelor
was not associated with any improvement in resolution of
ST elevation, implying that its observed benefit was depen-
dent on prevention of recurrent vascular events rather than
superior effects on early perfusion or protection from reper-
fusion injury [137]. These observations were contrary to the
findings frompre-clinical animal experiments demonstrating
that early exposure of ticagrelor has pleiotropic cardiopro-
tective effects that attenuate myocardial infarct size follow-
ing coronary occlusion and reperfusion [138], to a greater
degree than clopidogrel [139, 140]. This has implications
for the choice of initial antiplatelet agent in the manage-
ment of STEMI patients [141]. It has been observed that the
enteric absorption of ticagrelor is often delayed in STEMI
patients, especially when opiates such as morphine are co-
administered for pain relief [76–79]. This phenomenon may
explain the limited early benefit of ticagrelor and lack of dif-
ference in angiographic outcomes seen in the PLATO an-
giographic substudy, since rapid performance of PCI likely
provided insufficient time to allow ticagrelor’s effects to be-
come apparent in opiate-treated patients [142]. Administra-
tion of a parenteral P2Y12 inhibitor that reaches the circula-
tion within minutes and prior to emergency PCI could po-
tentially optimise the salvage of ischaemic myocardium and
minimise reperfusion injury, in addition to providing early
platelet inhibition to prevent stent thrombosis. Furtherwork
is therefore required to assess the benefit of intravenous can-
grelor or subcutaneous selatogrel prior to stenting, followed
by subsequent transition to oral ticagrelor [87, 141, 143, 144].
10. Ticagrelor in coronary-artery bypass
graft surgery
Around 10% of patients diagnosed with an ACS event are
treated by CABG [12], which is also an option for revascular-
isation in selected patients with CCS [2]. Factors that might
favour CABG over PCI as a revascularisation strategy include
triple-vessel or left main coronary artery disease, particularly
in patients with diabetes mellitus and those with chronic to-
tal occlusions of major coronary vessels [145]. A common
complication occurring after CABG is graft occlusion, which
can lead to recurrent ACS (including manifestation as sud-
den death), angina, or heart failure [146]. As a major sur-
gical procedure, CABG carries a significant risk of perioper-
ative bleeding that must be balanced against any benefits of
improved graft patency and broader protection from MACE
that antiplatelet therapy may offer [147].
An analysis of ticagrelor vs. the then standard-of-
care clopidogrel in aspirin-treated ACS patients undergoing
CABG was included in the PLATO study [148]. Out of the
trial population of 18,624, 1261 underwent CABG within
seven days of receiving study medication. Though under-
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powered to test robustly, there was evidence that the pri-
mary endpoint of MACE at 12 months occurred less fre-
quently when receiving ticagrelor versus clopidogrel (10.6%
vs. 13.1%, respectively; HR, 0.84; 95%CI 0.60–1.16; P =0.29).
Moreover, there was a strong signal of lower all-cause mor-
tality (4.7% vs. 9.7%; HR, 0.49; 95% CI 0.32–0.77; P < 0.01),
contributed to by both cardiovascular (4.1% vs. 7.9%; HR,
0.52; 95% CI 0.32–0.85; P < 0.01) and non-cardiovascular
death (0.7% vs. 2.0%; HR, 0.35; 95% CI 0.11–1.11; P = 0.07).
Importantly, there were no significant differences in CABG-
related bleeding outcomes between the groups (e.g., major
CABG-related bleeding 81.2% vs. 80.1%; HR, 1.07; 95% CI
0.80–1.43; P = 0.67).
Ticagrelor-based DAPT has also been compared with as-
pirin alone in patients undergoing CABG. In the Different
Antiplatelet Therapy Strategy After Coronary Artery Bypass
Graft Surgery (DACAB) trial, adding ticagrelor to aspirin led
to better saphenous vein graft patency compared to aspirin
alone (RR, 0.48; 95% CI 0.31–0.74; P < 0.001) [14]. DACAB
also included an analysis of ticagrelor monotherapy vs. as-
pirin alone, finding no significant differences in outcomes.
This comparison was further explored in the Ticagrelor in
CABG (TiCAB) trial, which randomised 1893 patients un-
dergoing CABG (around one-third for ACS) to receive sin-
gle antiplatelet therapy with either ticagrelor 90 mg BD or
aspirin 100 mg OD for 12 months after operation [149]. The
study was prematurely terminated on futility grounds, there
being no evidence of a benefit of ticagrelor over aspirin with
regards to the primary composite endpoint of cardiovascular
death, MI, repeat revascularization, and stroke (9.7% [tica-
grelor] vs. 8.2% [aspirin]; HR, 1.19; 95% CI 0.87–1.62; P =
0.28). There were also no observed differences in bleeding
outcomes.
Ticagrelor may offer advantages over thienopyridines to
ACS patients awaiting CABG as, due to its reversible bind-
ing, it has a more rapid offset [104]. Furthermore, there
are emerging strategies for more prompt reversal of tica-
grelor’s effects prior to CABG such as an haemadsorbent fil-
ter or infusion of a monoclonal antibody against the drug,
neither of which are feasible for thienopyridines due to their
irreversible action [111, 114]. Several observational studies
have examined how long before CABG ticagrelor should be
withheld in order to avoid excess bleeding risk. Data from
a Swedish registry suggested that discontinuation<72 hours
before surgery led to an increase in bleeding compared to>72
hours [150]. Furthermore, a single-centre study suggested
discontinuation >72 hours before CABG led to no excess
bleeding risk compared to patients who had received aspirin
alone [151]. A further analysis from the European Multi-
centre Study on Coronary Artery Bypass Grafting (E-CABG)
suggested that even discontinuing two days prior to surgery
was not associated with an increased risk of severe bleeding,
though there was a trend towards a greater need for platelet
transfusion than when receiving aspirin alone [152]. Phar-
macodynamic data suggest some recovery of ADP-induced
platelet aggregation responses from 24 hours after discon-
tinuation, but taking around four days for most patients to
reach a level above that required to avoid excess bleeding risk
[51]. Withholding ticagrelor for 3–5 days before CABG is
currently recommended, compared to 5 or 7 days for clopi-
dogrel and prasugrel, respectively [153, 154].
11. Studies of ticagrelor in ischaemic stroke
Ischaemic stroke is a common and often catastrophic con-
dition. The thrombotic subtype shares a commonpathophys-
iological mechanism and risk-factor profile with CAD [155].
Therefore, antiplatelet drugs may reduce the risk of throm-
botic stroke, but conversely increase the risk of bleeding, in-
cluding intracranial bleeding events. The mainstay of phar-
macological management of those at high risk of stroke has
been single antiplatelet therapy, which has demonstrated a
clear benefit at reducing the risk of large-artery atherothrom-
botic stroke but not small vessel occlusion or cardiac throm-
boembolism [156], with either aspirin or clopidogrel. There
is some evidence that clopidogrel may be modestly superior
to aspirin, particularly in patients with a history of stroke or
PAD [157]. Given ticagrelor may offer pharmacodynamic
advantages over aspirin or clopidogrel, it has therefore been
hypothesised that ticagrelor may offer superior clinical effi-
cacy after ischaemic stroke.
The Acute Stroke or Transient Ischaemic Attack
Treated with Aspirin or Ticagrelor and Patient Outcomes
(SOCRATES) trial was a multi-centre double-blind RCT
involving 13,199 patients with acute (<24 hours onset)
non-severe ischaemic stroke or high-risk transient ischaemic
attack (TIA) [19]. Patients such as those treated with
thrombolysis or thrombectomy, or with an indication for
therapeutic anticoagulation, were not eligible. Though
there was a trend towards lower MACE at 90 days when
receiving ticagrelor monotherapy compared to standard
aspirin monotherapy in this population, this did not reach
significance (6.7% [ticagrelor] vs. 7.5% [aspirin]; HR, 0.89;
95% CI 0.78–1.01; P = 0.07), though nominal secondary
analyses favoured ticagrelor with a lower incidence of
recurrent ischaemic stroke (5.8% vs. 6.7%; HR, 0.87; 95% CI
0.76–1.00; P = 0.046), all stroke (5.9% vs. 6.8%; HR, 0.86;
95% CI 0.75–0.99; P = 0.03) and major bleeding (0.5% vs
0.6%; HR, 0.83; 95% CI 0.52–1.34; P = 0.45), but with higher
incidences of minor bleeding and dyspnoea versus aspirin.
Some of the possible benefit of ticagrelor was seen in patients
treated with aspirin prior to randomisation, implying an
overlap of effects in the first few days after randomisation to
ticagrelor, and this raised the question of whether a DAPT
approach may be more effective.
The Acute Stroke or Transient Ischaemic Attack Treated
with Ticagrelor and Acetylsalicylic Acid for Prevention of
Stroke and Death (THALES) study was a double-blind,
placebo-controlled RCT [17] in a similar population to
SOCRATES that also included patients with symptomatic ar-
terial stenosis. This study showed that ticagrelor combined
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with aspirin reduced the incidence of the composite endpoint
of stroke or death compared with aspirin monotherapy at
30 days (5.5% [DAPT] vs. 6.6% [aspirin]; HR, 0.83; 95% CI
0.71–0.96; P = 0.02). DAPT also reduced the incidence of is-
chaemic stroke (5.0% vs. 6.3%; HR, 0.79; 95% CI 0.68–0.93;
P = 0.004) versus aspirin alone; however, there was no dif-
ference in overall disability (23.8% vs. 24.1%; HR, 0.98; 95%
CI 0.89–1.07; P = 0.61) between the two groups, and the rate
of severe bleeding was significantly higher in the ticagrelor
group at 30-days follow-up (0.5% vs. 0.1%; HR, 3.99; 95% CI
1.74–9.14; P = 0.001).
12. Studies of ticagrelor in peripheral artery
disease
Atherosclerosis can also lead to PAD, for example man-
ifesting as lower extremity artery disease or carotid artery
stenosis. Patients with PAD are also at an increased risk
of developing cerebral or myocardial ischaemia as a result
of widespread atherosclerotic disease. Clopidogrel has pre-
viously demonstrated superiority over aspirin in reducing
the risk of MACE (relative risk reduction, 23.8%; 95% CI
8.9–36.2; P = 0.003) in a subgroup of patients with PAD
[157], and a post-hoc analysis of the PLATO study suggested
similar beneficial trends during ticagrelor-based DAPT over
clopidogrel-based DAPT in patients with ACS and PAD
[158].
The Effects of Ticagrelor and Clopidogrel in Patients
With Peripheral Artery Disease (EUCLID) double-blind,
event-driven trial investigated the use of ticagrelor versus
clopidogrel monotherapy on the composite risk of MACE in
13,885 patients with symptomatic PAD over a median pe-
riod of 36 months [20]. The study showed that ticagrelor
was not superior to clopidogrel in preventing MACE (10.8%
[ticagrelor] vs. 10.6% [clopidogrel]; HR, 1.02; 95% CI 0.92–
1.13; P = 0.65), acute limb ischaemia (1.7% vs. 1.7%; HR, 1.03;
95% CI 0.79–1.33; P = 0.85) or major bleeding (1.6% vs. 1.6%;
HR, 1.10; 95% CI 0.84–1.43; P = 0.49). Ticagrelor did result
in greater rates of discontinuation than clopidogrel (15.4% vs.
11.1%, respectively), mainly as a result of dyspnoea and bleed-
ing. Based on this evidence, use of ticagrelor monotherapy
cannot currently be recommended for event prevention in
those with PAD, unless they have another indication. This is
reflected in the European Society of Cardiology (ESC) PAD
2017 guidelines [159]. The lack of benefit of ticagrelor, which
offers greater potency and consistency of platelet inhibition
than clopidogrel, was surprising and further work is required
to determine whether pleiotropic effects of clopidogrel may
be relevant during long-term treatment in this population
with extensive atherosclerotic disease, such as related to off-
target anti-inflammatory effects [64].
13. Adverse effect profile
Throughout clinical trials, ticagrelor-associated dyspnoea
has been consistently observed [16, 104, 115, 160]. In an anal-
ysis of the PLATO study, dyspnoea was reported in 14.5% of
those receiving ticagrelor vs. 8.7% receiving clopidogrel, the
excess being attributable to an effect of ticagrelor. Very few
events were of severe intensity (0.4% vs. 0.3%, respectively).
27.3% vs. 20.1% of dyspnoeic events had no identifiable ae-
tiology. Characteristics such as increased age and waist cir-
cumference as well as medical conditions including diabetes
and chronic kidney disease (CKD)were associatedwith an in-
creased risk of developing dyspnoea when treated with tica-
grelor [160].
Dyspnoea during ticagrelor therapy does not appear to
be associated with any changes in cardiac, pulmonary or
metabolic function, whether in patients with CCS [161] or
ACS [162]. Ticagrelor-related dyspnoea is typically of mild
or moderate intensity, most often develops within one week
of the initiation of treatment (median 23 days), and con-
tributes to a low number of patients (approximately 1%) dis-
continuing the regimen and switching to a thienopyridine
[160]. There appears to be amodest association between tica-
grelor plasma levels and dyspnoea.
In patients who reported dyspnoea in the PLATO study,
excluding those in whom it wasMI-related, the effect of tica-
grelor, compared with clopidogrel, on MACE appeared con-
sistent with the main PLATO study results (8.8% vs. 10.4%;
adjustedHR, 0.91; 95%CI 0.67–1.23; adjusted P = 0.542) [12].
There was also no impact on bleeding risk [160]. It there-
fore appears that ticagrelor-related dyspnoea is independent
of any physical manifestations of disease and does not affect
the efficacy or safety profile of ticagrelor therapy.
A perturbation in the afferent reflex carried by sensory
chemoreceptor, mechanoreceptor or vagal C-fibres from the
lungs and respiratory muscles may all contribute to an inap-
propriate perception of dyspnoea in the sensorimotor cortex
of the brain [163]. Two main mechanisms have been pro-
posed to explain how ticagrelor treatment can induce dys-
pnoea [164]. The first relates to ENT1 antagonism result-
ing in an elevated concentration of extracellular adenosine, a
compound that has been associated with dyspnogenic effects
in humans [165]. This is supported by the fact that theo-
phylline, an adenosine receptor antagonist, blocks the po-
tentiation of adenosine-induced dyspnoea by ticagrelor [56].
Against this theory is that dipyridamole, which has greater
potency than ticagrelor at preventing adenosine reuptake,
has not been associated with dyspnoea [166]. The second
relates to the inhibition of putative P2Y12 receptors on pul-
monary C-fibres [167]. This is perhaps best supported by
the observation that other reversible P2Y12 inhibitors, be-
longing to different chemical classes (e.g., cangrelor, elino-
grel and selatogrel), also induce dyspnoea. Though cangrelor
main metabolite very weakly inhibits adenosine reuptake,
there is no evidence that the other drugs or metabolites do
[143, 144, 168]. The lack of effect of thienopyridine P2Y12
inhibitors may be explained by the difference in pharmaco-
logical properties, relating to the ability of reversible P2Y12
inhibitors to constantly antagonise newly synthesised recep-
tors on nucleated C-fibres whereas therapeutic thienopyri-
dine active metabolite levels are short-lived [167].
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In terms of management, one of the major challenges fac-
ing clinicians is to determine whether dyspnoea in a patient
is related to a serious pathology or a side-effect of the medi-
cation. Ticagrelor-induced dyspnoea is generally a diagnosis
of exclusion, following a thorough history and examination,
but some mild cases that are not associated with limitation
of exercise capacity, orthopnoea or nocturnal dyspnoea can
be readily attributed to ticagrelor and reassurance provided,
particularly in patients who have been successfully revascu-
larised. While persistent and intolerable ticagrelor-induced
dyspnoea is uncommon, currently the only proven manage-
ment strategy is discontinuation [166] although dose reduc-
tion from90mgBD to 60mgBDmay be an alternative option
to try if dyspnoea is not severe.
In the PLATO study, ticagrelor was associated with a
greater incidence of asymptomatic ventricular pauses of 3
seconds or more in the first week (5.8% [ticagrelor] vs. 3.6%
[clopidogrel]; P = 0.01), and a greater increase in baseline
levels of serum uric acid (mean ± standard deviation: 15 ±
52% vs. 7± 31%; P < 0.001) and creatinine (11± 22% vs. 9
± 22%; P < 0.001) at 12 months compared with clopidogrel
[12]. Of note, there was no significant difference between
the treatment groups in the incidence of adverse events re-
lated to bradyarrhythmia, and the raised frequency of ventric-
ular pauses subsided by one month. It is uncertain whether
this effect of ticagrelor is associated with ENT1 blockade and
increased extracellular adenosine levels. Uric acid is a prod-
uct of purine (adenosine) metabolism [169], and can mani-
fest clinically as a slightly increased risk of gout during long-
term ticagrelor treatment, as demonstrated in the PEGASUS-
TIMI 54 study [13]. Finally, adenosine can alter renal haemo-
dynamics [170], resulting in a lower glomerular filtration
pressure and a subsequent increase in serum creatinine.
14. Ticagrelor in conjunctionwith oral
anticoagulant drugs
A major challenge facing clinicians is patients who have
indications for both dual antiplatelet therapy and oral antico-
agulant therapy, most commonly as a result of patients with
atrial fibrillation being treated with PCI. Recent trials have
indicated that vitaminK antagonists (VKA), such aswarfarin,
carry substantially higher risk of life-threatening bleeding,
most notably intracranial haemorrhage, compared with non-
VKA oral anticoagulants (NOAC), including when used in
conjunction with antiplatelet drug regimens [171–174]. The
2 × 2 factorial design of the AUGUSTUS study permitted
delineation of how much safety is improved by, firstly, using
the factor Xa inhibitor apixaban (at its licensed dose for pro-
phylaxis in atrial fibrillation) instead of a VKA and, secondly,
dropping aspirin from combination with anticoagulant and
a P2Y12 inhibitor [173]. Both of these led to reductions in
clinically-relevant bleeding, including in those with renal im-
pairment [175], without significant impact on the combined
endpoint of death and ischaemic events. However, there
were numerical trends towards more stent thrombosis when
aspirin was dropped from the antithrombotic regimen [176].
In AUGUSTUS and RE-DUAL, the majority of patients re-
ceived clopidogrel as the P2Y12 inhibitor [173] but aminority
received ticagrelor, allowing some non-randomised compar-
isons of efficacy and safety outcomes [177, 178]. These anal-
yses left some doubts about whether ticagrelormay safely and
effectively substitute for DAPT with aspirin and clopidogrel
in combination with a NOAC. The AUGUSTUS study sug-
gested that a triple regimen with ticagrelor, aspirin and oral
anticoagulant carries an unacceptable bleeding risk for rou-
tine use [178]. Whilst a dual regimen of ticagrelor and apix-
aban without aspirin makes pharmacological sense for opti-
mising prevention of stent thrombosis whilst avoiding exces-
sive bleeding, further work is required to assess this and com-
pare with other options.
15. Ticagrelor monotherapy studies and
studies of lower dose aspirin
This review has presented novel developments in an-
tiplatelet therapy and has emphasised the role of ticagrelor.
It is evident that the choice of pharmacological agents and
the duration of treatment is dependent on the risk factors
and clinical features of the individual patient. The clinical
development of ticagrelor for use in CAD initially placed it
as a substitute to clopidogrel in the context of DAPT i.e., in
combination with baseline aspirin therapy. However, a post-
hoc analysis of the PLATO trial found a significant interac-
tion between high (≥300 mg OD) aspirin dose and reduced
benefit of ticagrelor over clopidogrel in preventing MACE
[179], which led to questioning the benefits of aspirin along-
side ticagrelor. The GLOBAL LEADERS post-hoc analysis,
TWILIGHT and TICO studies indicate that the addition of
low-dose aspirin to ticagrelor increases the risk of bleeding
without an obvious benefit of anti-ischaemic protection af-
ter PCI, particularly in ACS patients. Bleeding is not only
associated with an increased risk of mortality [128, 129], but
mild cases can impact on quality of life and lead to premature
discontinuation of treatment [20, 180].
Based on a variety of studies, it is clear that combining as-
pirin and ticagrelor has additive effects [42, 181] and may
be required long term in certain patient populations that
are at high risk of arterial thrombotic events. For example,
PEGASUS-TIMI 54 and THEMIS-PCI consisted of high-risk
individuals who derived greater antithrombotic benefit from
DAPT than aspirin alone. In addition, the SOCRATES and
THALES trials showed that patients with ischaemic stroke
derived no benefit in ischaemic risk from ticagrelor alone
vs. aspirin, but did benefit from DAPT. For three of these
studies, the superior efficacy of DAPT also came at a cost
of substantially increased risk of bleeding. Therefore, it ap-
pears that combining P2Y12 inhibition by ticagrelor with
COX-1 inhibition by low-dose aspirin is important in cer-
tain high-risk patients. A novel strategy aims to optimise
aspirin dose in these patients to reduce the risk of bleeding
[9]. Currently, the lowest standard dose of aspirin is 75–100
386 Volume 22, Number 2, 2021
mg, but very-low doses (40 mg) have also demonstrated suf-
ficient cumulative inhibition of platelet activation via the ir-
reversible impairment of COX-1 derived TXA2 [182, 183].
Aspirin dose-dependently inhibits COX-2 [184, 185], an en-
zyme that is associated with a cardioprotective function,
whereby long-term inhibition may lead to adverse cardio-
vascular events [186, 187]. Therefore, lower-than-standard
dose aspirin could hypothetically reduce the risk of bleed-
ing and associated complications of COX-2 inhibition while
maintaining anti-thrombotic efficacy. A recent study (WIL-
LOW ACS) characterised a novel regimen of very-low-dose
aspirin (20 mg BD) plus ticagrelor over two weeks in 20 pa-
tients with recent ACS [188]. Compared with standard-dose
aspirin (75 mg OD) plus ticagrelor, the novel regimen re-
duced peak COX-1 inhibition, which was associated with a
significant reduction in bleeding time and without a signifi-
cant difference in arachidonic acid-induced platelet aggrega-
tion. In combination with ticagrelor, very-low-dose aspirin
is likely to provide adequate antithrombotic coverage partic-
ularlywhen administered twice-daily. A recent single-centre,
observational, non-randomised trial provides optimism for
this potential strategy as the results indicated that aspirin 50
mg OD reduced the frequency of bleeding events compared
with standard dose aspirin, without affecting the frequency
of MACE, in 1066 patients with CAD on ticagrelor ther-
apy [189]. Aspirin dose modification requires evaluation in
large-scale RCTs, with sufficient power to determine any im-
provement in net outcomes before implementation into clin-
ical practice.
16. ESC and AHA/ACC guideline
recommendations
The European Society of Cardiology (ESC) and American
College of Cardiology (ACC)/American Heart Association
(AHA) publish regular guidelines that represent the views of
experts in cardiology, based on the current knowledge and
understanding of cardiac conditions and management at the
time of publication. The following highlight the latest guide-
lines and represents the class of recommendation (I–III) and
the level of evidence (A–C) that are relevant to the use of tica-
grelor in CAD.
The ESC 2017 [5] and ACC Foundation/AHA 2013 [6]
STEMI guidelines both recommend the use of ticagrelor (180
mg loading dose, then 90 mg BD maintenance dose) as a
first-line P2Y12 inhibitor to be combined with aspirin in
the acute-phasemanagement of patients undergoing primary
PCI (ESC I, A; ACC/AHA I, B). For patients receiving fibri-
nolytic therapy and subsequent PCI, clopidogrel and aspirin
are recommended initially (both I, A), but ESC states that if
the index PCI is performed 48 hours after fibrinolysis, tica-
grelor or prasugrel may be considered instead of clopidogrel
(I, C). Maintenance antithrombotic therapy after PCI involv-
ing ticagrelor-based DAPT is recommended for at least one
year after STEMI unless there is an excessive risk of bleeding
(I, A; I, B), and ticagrelor plus aspirin may be considered for
longer than a year (ESC state ticagrelor 60 mg beyond one
year and up to three years; IIb, B; ACC/AHA state specifi-
cally following DES placement; IIb, C) in patients who toler-
ate DAPT and are at high risk of ischaemia.
The ESC 2020 [3] and AHA/ACC 2014 [4] NSTE-ACS
guidelines state that aspirin plus a P2Y12 inhibitor are rec-
ommended for one year after PCI (I, A; I, B). Ticagrelor is
recommended for both invasive and conservative strategies
and is preferred over clopidogrel; whereas prasugrel is only
recommended for patients who are intended for PCI and are
P2Y12 inhibitor-naïve (I, B) although the ESC NSTE-ACS
guidelines state that prasugrel should be considered in pref-
erence to ticagrelor in PCI-treated patients (IIa, B). The ESC
2020 guidelines do not recommend the routine use of P2Y12
inhibitors prior to invasive management when the coronary
anatomy is not known (III, A) but pre-treatment may be con-
sidered if patients are not planned for early invasive manage-
ment (IIb, C). Following intervention for NSTE-ACS, ESC
recommend amajority of patients receive DAPT for one year
(I, A), although there is a degree of freedom for the pre-
scribing clinician to select from various strategies that in-
clude prolonged duration, discontinuation or de-escalation of
themaintenance regimen: P2Y12 inhibitors are options long-
term with aspirin for secondary prevention for those at high
(IIa, A) or moderate (IIb, A) risk of ischaemia, without an ex-
cessive risk of bleeding; P2Y12 inhibitors may be stopped af-
ter three months if there is a high risk of bleeding (IIa, B); as-
pirinmay be stopped after three-to-six months depending on
the balance between the risks of ischaemia and bleeding (IIa,
A); prasugrel or ticagrelor may be switched to clopidogrel for
patients who are not considered at high risk of ischaemia (IIb,
A).
The ESC 2019 [2] CCS guidelines recommend that an oral
P2Y12 inhibitor or oral anticoagulant, in addition to aspirin,
should or may be considered for long-term secondary pre-
vention in CCS patients with sinus rhythm, who have a high
(IIa, A) or moderately increased (IIb, A) risk of ischaemia, re-
spectively, and are not at high risk of bleeding. Clopidogrel
75 mg OD and ticagrelor 60 mg BD are each indicated post-
MI in patients who have tolerated DAPT for one year, while
prasugrel requires an additional indication for the patient to
have received PCI and its use is cautioned in patients over
the age of 75 years. For post-PCI patients who are unable to
tolerate DAPT due to aspirin intolerance, or with high-risk
procedural features (e.g., suboptimal stent deployment, com-
plex left main stem, multivessel stenting, or characteristics
associated with a high risk of stent thrombosis), prasugrel or
ticagrelor may be considered instead of clopidogrel (IIb, C).
According to ESC guidelines, for NSTE-ACS and CCS pa-
tients with an indication for long-term anticoagulation and a
moderate or high risk of stent thrombosis, ticagrelor or pra-
sugrel plus an oral anticoagulant in dual antithrombotic ther-
apy may be considered as an alternative to triple antithrom-
botic therapy (IIb, C), and are not recommended for use in
triple therapy (III, C) [2, 3].
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Current ESC recommendations advise 12 months of
DAPT with aspirin and a P2Y12 inhibitor, preferably tica-
grelor or prasugrel, after CABG for ACS (I, C) [153]. Pro-
longed DAPT beyond one year can be considered in those
with a history of MI (IIb, C). However, if bleeding risk is
high, only 6 months of DAPT after CABG is recommended
and prasugrel should be avoided (IIa, C). In those undergoing
CABG for CCS, there is no current recommendation for the
routine use ofDAPTor ticagrelormonotherapy and these pa-
tients should remain on aspirin alone unless there is another
indication for an alternative regimen. ACC/AHA guidelines
also recommend 12 months of DAPT (including the option
of ticagrelor) after CABG for ACS (I, C) [190]. In contrast
to the ESC guidelines, 12 months of DAPT after CABG for
CCS is deemed reasonable (IIb, B) but clopidogrel is the only
P2Y12 inhibitor recommended in this scenario.
17. Future directions
Future work will exploit the reversibility of ticagrelor
with the further characterisation and development of meth-
ods for reversing ticagrelor’s effects in the event of patients
needing urgent surgery or developingmajor bleeding compli-
cations. More work is required to identify which patients are
best suited to ticagrelor monotherapy following PCI in order
to tailor efficacy and safety according to individual charac-
teristics. When dual antiplatelet therapy is required, further
work will assess potential benefits of twice-daily very-low-
dose aspirin regimens combined with ticagrelor. Tailoring
of the ticagrelor dose according to body weight may also help
refine short-term and long-term tolerability of ticagrelor in
the future. Learning how ticagrelor canwork alongside novel
secondary preventionmedicationswill provide opportunities
for refinement of secondary prevention of cardiovascular dis-
ease.
18. Conclusions
Ticagrelor is an oral P2Y12 receptor antagonist that
demonstrates some desirable pharmacological advantages
over thienopyridines, including reversibility of action. Its
greater potency of platelet inhibition comparedwith clopido-
grel translates to a reduction in MACE following ACS at the
cost of increased spontaneous bleeding events. In this review,
we have focussed on large randomised clinical trials and sub-
studies that underpin the use of ticagrelor in clinical practice
today, and highlight innovative antithrombotic strategies in-
volving ticagrelor that aim to optimise clinical outcomes in
specific patient populations by de-escalating the antiplatelet
coverage that subsequently reduces bleeding and may main-
tain efficacy. Ticagrelor remains a key drug in the manage-
ment of patients with CAD, and in particular ACS, that may
be extended to other atherosclerotic conditions. As research
continues in this field, pioneering clinical trials will establish
further uses and constraints of ticagrelor within specific pa-
tient populations and management strategies, and will deter-
mine whether the aforementioned novel regimens are incor-
porated into standard clinical practice.
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chaemic Attack Treated with Aspirin or Ticagrelor and Pa-
tient Outcomes; STEMI, ST-Elevation Myocardial Infarc-
tion; TAM, Ticagrelor Active Metabolite; THALES, Acute
Stroke or Transient Ischaemic Attack Treated with Tica-
grelor and Acetylsalicylic Acid for Prevention of Stroke and
Death; THEMIS, The Effect of Ticagrelor on Health Out-
comes in DiabetesMellitus Patients Intervention Study; TIA,
Transient Ischaemic Attack; TiCAB, Ticagrelor in CABG;
TICO, Ticagrelor Monotherapy After 3 Months in the Pa-
tients TreatedWithNewGeneration Sirolimus-eluting Stent
for ACS; TIMI, Thrombolysis in Myocardial Infarction;
tmax, time to maximum plasma concentration; TWILIGHT,
Ticagrelor with Aspirin or Alone in High-Risk Patients after
Coronary Intervention; TXA2, Thromboxane A2; t1/2, ter-
minal phase half-life; T2DM,Type 2DiabetesMellitus; VKA,
Vitamin K Antagonist.
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